11 November 2024
11 November 2024
The funding will be used to advance the commercialisation efforts of the company’s ZAP-X Gyroscopic Radiosurgery platform.
Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated observations”.
Based on the latest recommendation, the company anticipates receiving marketing authorisation for the system in the first quarter of 2025.
Offering a simpler alternative to PET scans and CSF analysis, blood-based biomarker tests could improve accessibility of Alzheimer’s diagnostics.
Early results from a trial of the company’s Lunit SCOPE system found patients examined with the device saw a 35% lower risk of disease progression.
The fully implanted system is designed to process input signals from an implantable source, as well as a wireless receiving device.
Spectral aims to finalise enrolment in early 2025 for its septic shock treatment Toraymyxin.
The deal between the two is set to advance the company’s blood test before rolling it out across more indications.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
